汉森制药(002412) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥216,830,821.90, representing a 3.17% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥42,856,985.53, a 35.95% increase year-over-year[4] - The basic earnings per share for Q3 2021 was ¥0.0852, reflecting a 36.10% increase compared to the same period last year[4] - Total operating revenue for Q3 2021 reached CNY 659.92 million, a 26.4% increase from CNY 521.90 million in the same period last year[23] - Net profit for Q3 2021 was CNY 113.49 million, representing a 33.9% increase compared to CNY 84.75 million in Q3 2020[24] - Earnings per share for Q3 2021 were CNY 0.2255, compared to CNY 0.1684 in the same quarter last year, reflecting a 34% increase[24] - The total comprehensive income for Q3 2021 increased by 43.37%, amounting to an increase of ¥36,691,119.89 compared to the previous year[11] - The company reported a total comprehensive income of CNY 121.30 million for Q3 2021, compared to CNY 84.61 million in Q3 2020, marking a 43.3% increase[24] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥2,043,914,429.74, an increase of 8.22% from the end of the previous year[4] - The company's current assets totaled CNY 575,472,832.57, compared to CNY 527,456,165.16 at the end of 2020, indicating an increase of about 9.1%[20] - The total non-current assets reached CNY 1,468,441,597.17, compared to CNY 1,361,185,499.33 at the end of 2020, which is an increase of about 7.9%[20] - Total liabilities as of Q3 2021 were CNY 327.90 million, an increase from CNY 293.92 million in the same period last year[23] - The company’s total liabilities decreased by 65.11% in contract liabilities, reflecting a reduction in pre-received customer payments[8] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥178,868,988.40, showing a 50.56% increase[4] - The company experienced a 50.56% increase in net cash flow from operating activities, primarily due to increased cash received from sales[11] - Cash flow from operating activities for Q3 2021 was CNY 178.87 million, an increase of 50.6% from CNY 118.80 million in Q3 2020[26] - The net cash flow from investing activities was -150,779,901.61, compared to -19,680,203.90 in the previous year, indicating a significant increase in cash outflows for investments[27] - Cash inflows from financing activities totaled 130,153,195.20, up from 110,191,243.32 year-over-year, reflecting an increase in borrowings[27] - The net cash flow from financing activities was -5,603,689.48, an improvement from -93,931,660.42 in the same period last year, showing reduced cash outflows for debt repayment and dividends[27] - The total cash and cash equivalents at the end of the period amounted to 126,046,267.58, compared to 121,797,903.72 at the end of the previous year, indicating a slight increase[27] Investments and Expenses - The company reported a 43.40% increase in investment income, amounting to an increase of ¥16,481,080.16 compared to the previous year[10] - Research and development expenses for Q3 2021 amounted to CNY 26.34 million, up 19.5% from CNY 21.95 million in the previous year[23] - Total operating costs for Q3 2021 were CNY 593.90 million, up 25.3% from CNY 474.33 million in Q3 2020[23] Compliance and Governance - The company has acknowledged the need for corrective measures following regulatory scrutiny, emphasizing its commitment to compliance and transparency[16] - The company held a board meeting to address prior accounting errors, ensuring adherence to accounting standards and improving financial reporting accuracy[17] - The third quarter report was not audited, which may affect the reliability of the financial data presented[30] Other Comprehensive Income - The company’s other comprehensive income increased by 90.21%, amounting to an increase of ¥7,803,735.27 compared to the previous year[9] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[23]